regulation of body fluid homeostasis and cardiovascular system. 10 However, accumulating evidence for the existence of an independent brain RAS prompted the search for additional physiological roles for this system. 11 The major biologically active peptide generated by RAS is angiotensin II (Ang II). 12 Ang II functions as a pleiotropic neuroregulator that stimulates 2 receptor types, the AT1 (AT1R) and AT2 (AT2R) receptors, both distributed in the brain. [13] [14] [15] [16] Increased brain AT1R stimulation can be pathological, leading to brain inflammation and neuronal injury. 17 Not surprisingly, common pro-inflammatory signaling cascades were found to be involved in the activation of AT1R and of Toll-like receptor 4 (TLR4) by Ang II and the endotoxin, lipopolysaccharide (LPS), respectively. 13 Modulation of brain inflammation associated with AD by angiotensin-related drugs has been the subject of great interest over recent years. 13, 16 Indeed, Ang II AT1R blockers (ARBs) are potent anti-inflammatory compounds that exert neuroprotective effects. 16, 18, 19 Increasing evidence suggests that ARBs may be effective therapeutic agents for brain diseases, including AD and
Parkinson's disease (PD). 16, 20 Recent studies conducted on AD transgenic mice models indicated preventive effects for AT1 receptor blockage on AD hallmarks. [21] [22] [23] Most of these rodent studies demonstrated neuroprotective and anti-inflammatory features for ARB treatment. Nevertheless, ARBs effect on Aβ load seems to change depending on administration procedure, AD model, and the dose used. Danielyan et al 21 showed reduced brain Aβ levels in APP/ PS1 transgenic mouse model following intranasal losartan treatment. However, Ongali et al 22 reported no alteration in amyloid levels in APP mice treated with losartan in drinking water. Previously, ARBs were reported as modulators of macrophages polarization in different tissues. [24] [25] [26] However, the role of brain RAS in microglial polarization toward neuroprotective phenotype is less clear. 27 We and others showed induction of neuroprotection through microglial polarization by telmisartan. 18, 28 In PD mouse model, ARB treatment protected from dopaminergic neurons death, reduced motor deficits, and inhibited microglial activation. 29, 30 Candesartan (a bloodbrain barrier-entering ARB) reversed the neurotoxic effects of AT1R overstimulation in animal models of systemic inflammation. [31] [32] [33] [34] Candesartan, subcutaneous administered, to LPS-injected hypertensive or normotensive rats decreased the LPS-induced gliosis in the brain parenchyma. [32] [33] [34] Interestingly, a recent study indicated a great neuroprotective potential for candesartan in AD as it affected the expression of hundreds of genes in AD patients' cortex and hippocampus. 31 The effect of candesartan on Aβ expression in AD mouse brains has been hardly investigated before. In this study, we investigated the effect of intranasal treatment with candesartan on disease pathology in the 5XFAD mouse brain. Candesartan was introduced to 2-month-old 5XFAD mice, when amyloid deposition and gliosis begin. Moreover, the effect of candesartan, studied here, on modulation of microglial polarization is not known. 27 Finally, we investigated for the first time, whether candesartan influences Aβ uptake by microglial cells. 
| MATERIALS AND METHODS

| Mice
The 5XFAD model mice were used. This model harbors 3 familial AD (FAD) mutations in the human APP695 and 2 mutations in the human presenilin-1 genes. 9 Animals were housed in cages as detailed. 18 Mice, 2 months of age, were placed in a supine position and treated intranasally every day, for 8 weeks, with candesartan or vehicle (3 μL drop to each nostril). Candesartan was dissolved in N,N-dimethylformamide/polyethylene glycol 400/saline (2:6:2) solvent at a concentration of 2 mg/mL. 35 Mice were randomly di- 
| Cell viability
| Nitric oxide (NO) production levels
The Griess reaction was used to measure supernatant nitrite concentration as an indicator of NO production. Well supernatant was mixed with an equal volume of Griess reagent (Sigma-Aldrich, Cat No. G4410) in a 96-well plate and incubated for 15 minutes. Mixture absorbance was measured at 540 nm using a microplate reader (model 680, BioRad, Hercules, CA). NO levels were normalized to cell numbers.
| Enzyme-linked immunosorbent assay (ELISA)
Supernatant tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1) (Cat No. DY410 and DY1679), and interleukin 1-β (IL1-β) (Cat No. 559603) levels were assayed using ELISA kits (R&D Systems, Minneapolis, MN and BD Biosciences, San Diego, CA) according to the manufacturers' instructions.
| SDS-PAGE gel electrophoresis and Western blot analysis
Whole-cell and whole-brain protein extracts were obtained using lysis buffer following rinsing or cold PBS cardiac perfusion, respectively. Lysates were subjected to 7.5% or 10% PAGE and transferred onto nitrocellulose membranes. Membranes were blocked with 4%
BSA and incubated overnight at 4°C with the following antibodies: 
| Imaging analysis
Aβ plaque and CD11b staining in hippocampal and cortical areas were 
| Statistical analysis
Data are presented as the mean ± SEM. Significance assessment (considered at P < 0.05) between experimental groups was determined using one-way analysis of variance (ANOVA) followed by post hoc multiple comparison test (Tukey-Kramer multiple comparison test).
| RESULTS
| Candesartan with or without LPS does not show any cytotoxic effect in BV2 microglial cells
We first examined the effect of candesartan on viability of BV2 microglial cells (Figure 1 ). We used actinomycin D, a cell proliferation inhibitor, as positive control. Actinomycin D (0.5 μg/mL) significantly inhibited BV2 proliferation by 98%. Candesartan (1 μmol/L and 5 μmol/L), LPS (7 ng/mL), or both compounds given together do not show any cytotoxic effect in BV2 microglia (Figure 1 ).
| Candesartan decreases LPS-induced NO, TNF-α, and TGF-β1 but not IL1-β release from microglial cells
The extent to which candesartan can serve as an anti-inflammatory compound in microglia was investigated by taking measurements of inflammatory cytokine production levels following LPS stimulation.
We stimulated BV2 microglia ( 
| Candesartan does not affect Aβ-degrading enzyme expression levels in 5XFAD-treated mice brains
Next, we investigated whether Aβ clearance by candesartan is associated with induced expression levels of Aβ-degrading enzyme.
Whole-brain protein lysates from 5XFAD or WT mice treated with candesartan or the vehicle were measured for NEP and IDE protein levels. The expression levels of NEP were dramatically reduced in the brains of 5XFAD-treated mice by more than 2-fold, when compared to brains of age-matched WT mice ( Figure 5A ). However, no significant alterations in NEP expression levels were observed between the 2 5XFAD-treated groups following candesartan or vehicle treatment ( Figure 5A ). Similarly, intranasal administration of candesartan did not affect IDE expression levels in the brains of 5XFAD-treated mice, as compared to vehicle-treated mice ( Figure 5B ).
| Candesartan induces Aβ phagocytosis by microglia
As candesartan did not affect the amyloid burden load via changes in degrading enzyme levels, we considered an alternative mechanism for Aβ clearance by assessing Aβ phagocytosis analysis in microglial cells 
| DISCUSSION
Microglial cells are the major cellular regulators of innate immune responses in the central nervous system (CNS). 2, 36 Brain injury and neurodegenerative diseases shift microglia toward an activated phenotype. 36 LPS induces brain inflammation which is associated with glial cells activation. 37 LPS and Aβ peptides may both activate microglia through the same receptors, namely TLR4 and CD14. 38, 39 During the host defense response, activated glial cells release neurotoxic factors, such as TNF-α, IL1-β, and NO. 40, 41 In the present study, candesartan was shown to reduce the production of NO, TNF-α, and TGF-β1 but not of IL1-β (Figure 2 ) in LPS-induced glial cells. Benikey et al 33 showed reduced IL1-β levels in 4-hour LPSstimulated cortical microglia (100 ng/mL) following 2-hour pretreatment with candesartan (10 μmol/L). In the present study, a 24-hour treatment with candesartan did not change IL1-β release compared to LPS (7 ng/mL)-stimulated BV2 microglial cells. Changes in modulation of IL1-β release between studies may be due to different concentrations and incubation times with LPS and candesartan. A similar effect of candesartan on TNF-α and nitrite levels in inflammation-induced F I G U R E 3 Candesartan decreased the inflammatory response and elevated anti-inflammatory factors' expression in LPS-induced microglia. BV 2 . Cells were incubated for 24 h with LPS (7 ng/mL) in the presence or absence of 1 or 5 μmol/L candesartan (Can). Whole-cell protein lysates were prepared and relative levels of iNOS (130 kDa) (A), COX-2 (69 kDa) (B), and ARG-1 (35-38 kDa) (C) were determined by Western analysis using target-specific primary antibodies and compared to β-actin (42 kDa) levels. Means ± SEM of representatives of 3 independent experiments are presented (n = 3 experiments, each experiment included 2-3 samples for treatment). One-way ANOVA and a Tukey-Kramer multiple comparison test were used for statistical significance. ***P < 0.001 vs control (nonstimulated cells); ^^^P < 0.001 vs LPS; ^^P < 0.01 vs LPS; ^P < 0.05 vs LPS;
TORIKA eT Al.
F I G U R E 4
Candesartan reduced Aβ expression and microglial activation in the hippocampus of 5XFAD mice. Eight-week-old mice were treated intranasally with either candesartan (Can) or the vehicle for 2 mo. At the end of the experiment, the mice were sacrificed, cardiac perfusion was performed, and brain sections were obtained. Sections were immunolabeled with anti-CD11b (green) and anti-Aβ (red) antibodies and counterstained with DAPI (blue). Representative cortical (A, E) and hippocampal (C, G) layers from WT or 5XFAD mice treated with candesartan (1 mg/kg/d) or with the vehicle are shown. The experiment included 6-8 mice per group (n = 21 in total). The average sums of Aβ-stained (B, F) and of CD11b-stained (D, H) areas were quantified and are represented as the mean ± SEM percentage of the stained area in the corresponding vehicle-treated group in at least 3 repeats. Statistical significance was determined using one-way ANOVA, followed by a TukeyKramer multiple comparison test. ***P < 0.001 vs WT+Tel; ^^^P < 0.001 vs 5XFAD+vehicle; ^P < 0.05 vs 5XFAD+vehicle. Scale bar is 200 μm isolated glial cell lines was shown by Bhat et al 42 . TGF-β1 is an inflammatory cytokine that plays a dual role in T cells during inflammation, with its role being determined by the surrounding cell milieu. 43 Lanz et al 44 suggested that during neuroinflammation, microglia are the main producers of TGF-β1 in the CNS and are highly responsive to Ang II.
The reduction in TGF-β1 levels following candesartan treatment shown in our study is in agreement with Lanz et al, whose study focused on the role of AT1R in chronic progressive experimental autoimmune encephalomyelitis (EAE) and showed a decrease in TGF-β1 production following candesartan treatment in primary glial cells. 44 As part of their functional plasticity, microglia can induce the production of anti-inflammatory cytokines, together with phagocytosis of cellular debris. 45 ARG-1 is one of several cell integrity-associated markers that are expressed as microglia assume a neuroprotective phenotype. 46 As ARG-1 and iNOS compete for the same substrate, arginine, enhanced expression of ARG-1 may result in reduced microglial release of NO. 47 Phagocytosis of Aβ by microglia also serves a neuroprotective role in the brain. 45 It was previously suggested that classical activated microglia (M1) might be less able to properly uptake Aβ while alternatively activated microglia (M2) are more efficient phagocytes. 48 Several in vitro and in vivo studies have provided evidence for the degradation of Aβ aggregates by microglia. [49] [50] [51] The ability of microglia to digest Aβ deposits is impaired during progression of the AD. 45, 50 Therefore, it is plausible that improved Aβ uptake by microglia would ameliorate the progression of the disease. Our results suggest that candesartan, in addition to its anti-inflammatory properties, may
Intranasal administration of candesartan does not alter NEP or IDE expression levels in the brains of 5XFAD mice. Eight-weekold mice were treated intranasally with either candesartan (Can) or the vehicle for 2 mo. At the end of the experiment, the mice were sacrificed and whole-brain protein lysates were prepared and levels of NEP (100 kDa) (A), IDE (115 kDa) (B) proteins were determined relative to β-actin (42 kDa) levels by Western analysis using target-specific primary antibodies. Representative blots and graphs from wild-type (WT+Can) or 5XFAD mice treated with 1 mg/kg/d candesartan (Can) (5XFAD+Can) or with the vehicle (5XFAD+Vehicle) are shown. Means ± SEM of representatives of 6-8 mice per group (n = 21 in total) are presented. One-way ANOVA and a Tukey-Kramer multiple comparison test were used for statistical significance. ***P < 0.001 vs WT+Can Indeed, candesartan treatment not only reduced expression levels of the iNOS and COX-2 in LPS-induced BV2 cells ( Figure 3A,B) , but also increased expression levels of ARG-1 protein ( Figure 3C ) and phagocytosis of Aβ 1-42 peptides also in primary microglial cells ( Figure 6 ). It is well established that neuroprotective effects mediated by ARBs, including candesartan, also depend on their agonism for the neuroprotective nuclear receptor peroxisome proliferator-activated receptor (PPAR-γ). 13, 16 Not surprisingly, enhanced phagocytosis of Aβ peptides by microglia was reported following activation of this receptor. 52 Aβ peptides can be degraded by glial proteases. 53 IDE and NEP were reported to be metalloendopeptidases involved in Aβ peptide cleavage. 53, 54 As candesartan reduced Aβ in 5XFAD mice, we hypothesized that an increase in NEP and IDE expression would be observed following candesartan treatment. However, no changes in IDE or NEP expression levels in 5XFAD mice brains following candesartan treatment were observed.
Candesartan treatment was previously reported to modulate oligomerization of Aβ peptides in vitro. 55 However, its effect on Aβ load was hardly investigated previously, let alone in AD mice model. Administration of candesartan to LPS-injected spontaneously hypertensive rats was shown to reverse amyloidogenesis in the cortical and hippocampal layers. 56 The present study, conducted on 5XFAD mice, showed that 2-month intranasal treatment with candesartan resulted in reduced Aβ deposits and microglial accumulation in the hippocampus but not in the cortex (Figure 4 ). This may result from different age-related and area-dependent expression levels of amyloid burden and gliosis in 5XFAD mouse brains. Initially, young 5XFAD mice exhibit Aβ pathology and microglial accumulation in the cortex, and as the mice age, amyloid deposits are also observed in the hippocampus. 9 It seems that robust expression of Aβ and gliosis is harder to modulate by intranasal candesartan (as indicated in the cortex layer of 5XFAD mice in Figure 4 ). However, as intranasal candesartan reduced Aβ deposition in the hippocampus of young (4-month-old) 5XFAD mice (Figure 4) , and considering that candesartan was shown to ameliorate AD-related risk factors, 14,51,52,57 candesartan might be considered as a drug for the early stages of AD.
Nevertheless, shorter (3 weeks) intranasal treatment with candesartan resulted in reduced CD11b but not Aβ expression in the cortex of 5XFAD mice (data not shown). Hence, we assume that the modulatory effect of candesartan on cortical microglial activation precedes later changes of amyloid burden and gliosis observed in different brain areas. In this context, we previously also demonstrated a significant effect of telmisartan, a potent ARB, on gliosis and amyloid burden in age-matched 5XFAD mice in the early stages of the disease. 19 It should be noted that despite promising advantages, chronic intranasal delivery may have some limitations, including poor drugs permeability across nasal epithelium, mucociliary clearance, and irritation or damage to the nasal mucosa. 58 The first 2 mentioned limitations can be minimized by mucoadhesive formulations or usage of chemical penetration enhancers, improving the bioavailability of drugs that are incorporated. 59 Mucosal epithelial damage prevention seems to be one of the main challenges of intranasal administration, and to date, this problem awaits solution. Nevertheless, it should be noted that oral administration also has its own limitations including incomplete drug delivery, increased drug-drug interactions, and exposure to first pass effect.
| CONCLUSIONS
This study demonstrated that blockage of AT1R using candesartan, a potent ARB compound, results in an anti-inflammatory effect on microglia and AD mice brains. This effect was accompanied by a shifting of microglia toward a more neuroprotective phenotype and induced phagocytosis of the Aβ . Taken together with the ability of candesartan to prevent AD risk factors, one could envision potential intervention in glial activation and AD by this compound.
